Regenecyte is under clinical development by StemCyte and currently in Pre-Registration for Unspecified Hematological Disorders.

Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeutics, says Fact. ROCKVILLE , MD, UNITED STATES, December 13 ...

Keywords: Extracellular Vesicles, Hematological Disorders, Anemia, Platelet-Derived EVs, Pathophysiology Important Note: All contributions to this Research Topic must be within the scope of the ...

We provide state-of-the-art patient care, innovative education initiatives, and cutting-edge research in hematologic conditions such as sickle cell disease, hemostasis & thrombosis, complement ...

Vanda Pharmaceuticals Inc. VNDA generates revenues from the sale of its three commercial products, Fanapt, Hetlioz and ...

Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeutics, says Fact.MR. ROCKVILLE , MD, UNITED STATES, December 13,..

[1] Anemia and its predictors among chronic kidney disease patients in Sub-Saharan African countries: A systematic review and meta-analysis ...

The hematology diagnostics market is projected to be valued at USD 780.0 million in 2023 and is rising to USD 2.0 billion by 2033. The market of hematology diagnostics is expected to record a CAGR of ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell ...

Asunercept is under clinical development by Apogenix and currently in Phase I for Unspecified Dermatological Disorders.

The top 5 most-viewed videos of 2024 highlighted advancements in therapies, heart disease screening, pediatric palliative ...